Am. J. Respir. Cell Mol. Biol., Volume 22, Number 3, March, 2000 316-322

Nonproteolytic Role for the Urokinase Receptor in Cellular Migration In Vivo

David A. Waltz, Ross M. Fujita, Xuiwei Yang, Lisa Natkin, Shaoqiu Zhuo, Craig J. Gerard, Steven Rosenberg, and Harold A. Chapman

Department of Medicine, Children's Hospital; Department of Medicine, Brigham and Women's Hospital; Harvard Medical School, Boston, Massachusetts; and Chiron Corporation, Emeryville, California

The urokinase receptor (uPAR) binds and localizes urokinase activity at cellular surfaces, facilitating fibrinolysis and cellular migration at sites of tissue injury. uPAR also participates in cellular signaling and regulates integrin-dependent adhesion and migration in vitro. We now report evidence that uPAR occupancy regulates cellular migration in vivo in the absence of functional urokinase. Recombinant murine KC (1.5 µg), a potent neutrophil chemoattractant, was delivered to the lungs of wild-type, urokinase-deficient or uPAR-deficient mice 18 h after intraperitoneal injection of 200 µg human immunoglobulin G (IgG) or a fusion protein composed of an amino-terminal receptor-binding fragment of urokinase and a human IgG Fc fragment (GFD-Fc). Whole lung lavage for recovery of leukocytes was performed 4 h later. KC treatment resulted in a 100-fold increase in lavage neutrophils. GFD-Fc injection resulted in > 50% reduction in neutrophil influx in both wild-type and urokinase-deficient animals but had no effect on uPAR / mice. A concomitant reduction in alveolar protein leakage but no change in numbers of circulating neutrophils accompanied this attenuated inflammatory response. The reduction in neutrophil influx induced by GFD-Fc is thus related to uPAR occupancy and yet not due to disruption of uPAR-mediated proteolysis. These observations verify that protease-independent functions of uPAR operate in vivo and identify uPAR as a potential target for regulation of inflammatory processes characterized by neutrophil-mediated injury.

This article has been cited by other articles:

				F. Gueler, S. Rong, M. Mengel, J.-K. Park, J. Kiyan, T. Kirsch, I. Dumler, H. Haller, and N. Shushakova Renal Urokinase-Type Plasminogen Activator (uPA) Receptor but not uPA Deficiency Strongly Attenuates Ischemia Reperfusion Injury and Acute Kidney Allograft Rejection J. Immunol., July 15, 2008; 181(2): 1179 - 1189. [Abstract] [Full Text] [PDF]

				B. Fuhrman, J. Khateeb, M. Shiner, O. Nitzan, R. Karry, N. Volkova, and M. Aviram Urokinase Plasminogen Activator Upregulates Paraoxonase 2 Expression in Macrophages Via an NADPH Oxidase-Dependent Mechanism Arterioscler. Thromb. Vasc. Biol., July 1, 2008; 28(7): 1361 - 1367. [Abstract] [Full Text] [PDF]

				P. Begin, K. Tremblay, D. Daley, M. Lemire, S. Claveau, C. Salesse, S. Kacel, A. Montpetit, A. Becker, M. Chan-Yeung, et al. Association of Urokinase-type Plasminogen Activator with Asthma and Atopy Am. J. Respir. Crit. Care Med., June 1, 2007; 175(11): 1109 - 1116. [Abstract] [Full Text] [PDF]

				A. M. Brooks, M. E. Bates, R. F. Vrtis, N. N. Jarjour, P. J. Bertics, and J. B. Sedgwick Urokinase-Type Plasminogen Activator Modulates Airway Eosinophil Adhesion in Asthma Am. J. Respir. Cell Mol. Biol., October 1, 2006; 35(4): 503 - 511. [Abstract] [Full Text] [PDF]

				W. Xiao, Y.-P. Hsu, A. Ishizaka, T. Kirikae, and R. B. Moss Sputum Cathelicidin, Urokinase Plasminogen Activation System Components, and Cytokines Discriminate Cystic Fibrosis, COPD, and Asthma Inflammation Chest, October 1, 2005; 128(4): 2316 - 2326. [Abstract] [Full Text] [PDF]

				N. Shushakova, G. Eden, M. Dangers, J. Zwirner, J. Menne, F. Gueler, F. C. Luft, H. Haller, and I. Dumler The Urokinase/Urokinase Receptor System Mediates the IgG Immune Complex-Induced Inflammation in Lung J. Immunol., September 15, 2005; 175(6): 4060 - 4068. [Abstract] [Full Text] [PDF]

				K. H. Minor, C. R. Schar, G. E. Blouse, J. D. Shore, D. A. Lawrence, P. Schuck, and C. B. Peterson A Mechanism for Assembly of Complexes of Vitronectin and Plasminogen Activator Inhibitor-1 from Sedimentation Velocity Analysis J. Biol. Chem., August 5, 2005; 280(31): 28711 - 28720. [Abstract] [Full Text] [PDF]

				S. Kunigal, A. Kusch, N. Tkachuk, S. Tkachuk, U. Jerke, H. Haller, and I. Dumler Monocyte-expressed urokinase inhibits vascular smooth muscle cell growth by activating Stat1 Blood, December 15, 2003; 102(13): 4377 - 4383. [Abstract] [Full Text] [PDF]

				P. G. McGuire, T. R. Jones, N. Talarico, E. Warren, and A. Das The Urokinase/Urokinase Receptor System in Retinal Neovascularization: Inhibition by A6 Suggests a New Therapeutic Target Invest. Ophthalmol. Vis. Sci., June 1, 2003; 44(6): 2736 - 2742. [Abstract] [Full Text] [PDF]

				S. S. Lakka, C. S. Gondi, N. Yanamandra, D. H. Dinh, W. C. Olivero, M. Gujrati, and J. S. Rao Synergistic Down-Regulation of Urokinase Plasminogen Activator Receptor and Matrix Metalloproteinase-9 in SNB19 Glioblastoma Cells Efficiently Inhibits Glioma Cell Invasion, Angiogenesis, and Tumor Growth Cancer Res., May 15, 2003; 63(10): 2454 - 2461. [Abstract] [Full Text] [PDF]

				E. M. Powell, D. B. Campbell, G. D. Stanwood, C. Davis, J. L. Noebels, and P. Levitt Genetic Disruption of Cortical Interneuron Development Causes Region- and GABA Cell Type-Specific Deficits, Epilepsy, and Behavioral Dysfunction J. Neurosci., January 15, 2003; 23(2): 622 - 631. [Abstract] [Full Text] [PDF]

				A. E. May, R. Schmidt, S. M. Kanse, T. Chavakis, R. W. Stephens, A. Schomig, K. T. Preissner, and F.-J. Neumann Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction Blood, November 15, 2002; 100(10): 3611 - 3617. [Abstract] [Full Text] [PDF]

				V. Leksa, S. Godar, M. Cebecauer, I. Hilgert, J. Breuss, U. H. Weidle, V. Horejsi, B. R. Binder, and H. Stockinger The N Terminus of Mannose 6-Phosphate/Insulin-like Growth Factor 2 Receptor in Regulation of Fibrinolysis and Cell Migration J. Biol. Chem., October 18, 2002; 277(43): 40575 - 40582. [Abstract] [Full Text] [PDF]

				D. Palmieri, J. W. Lee, R. L. Juliano, and F. C. Church Plasminogen Activator Inhibitor-1 and -3 Increase Cell Adhesion and Motility of MDA-MB-435 Breast Cancer Cells J. Biol. Chem., October 18, 2002; 277(43): 40950 - 40957. [Abstract] [Full Text] [PDF]

				A. W. Rijneveld, M. Levi, S. Florquin, P. Speelman, P. Carmeliet, and T. van der Poll Urokinase Receptor Is Necessary for Adequate Host Defense Against Pneumococcal Pneumonia J. Immunol., April 1, 2002; 168(7): 3507 - 3511. [Abstract] [Full Text] [PDF]

				G. van der Pluijm, B. Sijmons, H. Vloedgraven, C. van der Bent, J.-W. Drijfhout, J. Verheijen, P. Quax, M. Karperien, S. Papapoulos, and C. Lowik Urokinase-Receptor/Integrin Complexes Are Functionally Involved in Adhesion and Progression of Human Breast Cancer in Vivo Am. J. Pathol., September 1, 2001; 159(3): 971 - 982. [Abstract] [Full Text] [PDF]

				D. J. Webb, K. S. Thomas, and S. L. Gonias Plasminogen Activator Inhibitor 1 Functions as a Urokinase Response Modifier at the Level of Cell Signaling and Thereby Promotes MCF-7 Cell Growth J. Cell Biol., February 20, 2001; 152(4): 741 - 752. [Abstract] [Full Text] [PDF]